Emestrin-Type Epidithiodiketopiperazines Inhibited Gasdermin D-Mediated Pyroptosis via Caspase-3/7 Activation

Abstract

Sepsis, a life-threatening dysregulated host response to infection, is frequently exacerbated by pyroptosis—a programmed, proinflammatory cell death process mediated by Gasdermin D (GSDMD) activation. Using high-throughput screening, we identified emestrin-type epidithiodiketopiperazines (ETPs) as potent inhibitors of GSDMD cleavage during pyroptosis in Tohoku Hospital Pediatrics-1 (THP-1, a human acute monocytic Leukemia cell line)-derived macrophages. Combined surface plasmon resonance and western blotting analyses demonstrated that these ETPs activate caspase-3/7, which in turn cleaves GSDMD at aspartic acid residue 87 to generate a p10 fragment. This process prevents the formation of the pore-forming p30 fragment, thereby mitigating its associated inflammatory effects. Building on these results, in vivo studies showed that a low dose of the lead emestrin-type ETP (compound 2) protected against lethal lipopolysaccharide (LPS)-induced septic shock and attenuated lung inflammation. This protective effect was further validated in the clinically relevant cecal ligation and puncture (CLP) model, where compound 2 significantly enhanced survival by suppressing the infiltration of GSDMD-positive neutrophils and monocytes. scRNA-seq of murine lung tissue showed that compound 2 suppressed LPS-induced systemic inflammation by inhibiting moDC maturation. Collectively, these findings establish the therapeutic potential of targeting GSDMD-driven pyroptosis with ETPs in sepsis and suggest their promise for clinical translation.

Keywords

apoptosis / gasdermin D / high-throughput screening / pyroptosis / sepsis

References

[1] J. Prest, T. Nguyen, T. Rajah, et al., “Sepsis-Related Mortality Rates and Trends Based on Site of Infection,” Critical Care Explorations 4, no. 10 (2022): e0775.

[2] I. Karampela and P. C. Fragkou, “Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock,” Medicina (Kaunas, Lithuania) 58, no. 7 (2022): 844.

[3] Y. Chen, X. Wang, J. Wang, et al., “Revealing Novel Pyroptosis-related Therapeutic Targets for Sepsis Based on Machine Learning,” BMC Medical Genomics 16, no. 1 (2023): 23.

[4] R. Wen, Y. P. Liu, X. X. Tong, et al., “Molecular Mechanisms and Functions of Pyroptosis in Sepsis and Sepsis-associated Organ Dysfunction,” Frontiers in Cellular and Infection Microbiology 12 (2022): 962139.

[5] R. Shao, X. Lou, J. Xue, et al., “Review: The Role of GSDMD in Sepsis,” Inflammation Research 71, no. 10–11 (2022): 1191–1202.

[6] D. Bertheloot, E. Latz, and B. S. Franklin, “Necroptosis, Pyroptosis and Apoptosis: An Intricate Game of Cell Death,” Cellular & Molecular Immunology 18, no. 5 (2021): 1106–1121.

[7] Z. Dai, W. C. Liu, X. Y. Chen, et al., “Gasdermin D-mediated Pyroptosis: Mechanisms, Diseases, and Inhibitors,” Frontiers in Immunology 14 (2023): 1178662.

[8] L. Li, M. S. Dickinson, J. Coers, et al., “Pyroptosis in Defense Against Intracellular Bacteria,” Seminars in Immunology 69 (2023): 101805.

[9] Z. Li, S. Ji, M. L. Jiang, et al., “The Regulation and Modification of GSDMD Signaling in Diseases,” Frontiers in Immunology 13 (2022): 893912.

[10] N. Van Opdenbosch and M. Lamkanfi, “Caspases in Cell Death, Inflammation, and Disease,” Immunity 50, no. 6 (2019): 1352–1364.

[11] A. Ayala, M. Perl, F. Venet, et al., “Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets,” Current Pharmaceutical Design 14, no. 19 (2008): 1853–1859.

[12] R. S. Hotchkiss and D. W. Nicholson, “Apoptosis and Caspases Regulate Death and Inflammation in Sepsis,” Nature Reviews Immunology 6, no. 11 (2006): 813–822.

[13] C. B. Medina, P. Mehrotra, S. Arandjelovic, et al., “Metabolites Released From Apoptotic Cells Act as Tissue Messengers,” Nature 580, no. 7801 (2020): 130–135.

[14] X. Zheng, W. Chen, F. Gong, et al., “The Role and Mechanism of Pyroptosis and Potential Therapeutic Targets in Sepsis: A Review,” Frontiers in Immunology 12 (2021): 711939.

[15] F. Liu, L. Ghimire, A. Balasubramanian, et al., “Neutrophil-specific Depletion of Gasdermin D Does Not Protect Against Murine Sepsis,” Blood 141, no. 5 (2023): 550–554.

[16] N. Kayagaki, I. B. Stowe, B. L. Lee, et al., “Caspase-11 Cleaves Gasdermin D for Non-canonical Inflammasome Signalling,” Nature 526, no. 7575 (2015): 666–671.

[17] W. T. He, H. Wan, L. Hu, et al., “Gasdermin D Is an Executor of Pyroptosis and Required for Interleukin-1beta Secretion,” Cell Research 25, no. 12 (2015): 1285–1298.

[18] J. J. Hu, X. Liu, S. Xia, et al., “FDA-approved Disulfiram Inhibits Pyroptosis by Blocking Gasdermin D Pore Formation,” Nature Immunology 21, no. 7 (2020): 736–745.

[19] J. K. Rathkey, J. Zhao, Z. Liu, et al., “Chemical Disruption of the Pyroptotic Pore-forming Protein Gasdermin D Inhibits Inflammatory Cell Death and Sepsis,” Science Immunology 3, no. 26 (2018): eaat2738.

[20] F. Humphries, L. Shmuel-Galia, N. Ketelut-Carneiro, et al., “Succination Inactivates Gasdermin D and Blocks Pyroptosis,” Science 369, no. 6511 (2020): 1633–1637.

[21] X. Jiang, X. Zhang, X. Cai, et al., “NU6300 covalently Reacts With Cysteine-191 of Gasdermin D to Block Its Cleavage and Palmitoylation,” Science Advances 10, no. 6 (2024): eadi9284.

[22] E. Coy-Barrera, I. V. Ogungbe, and T. J. Schmidt, “Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Therapeutics,” Molecules (Basel, Switzerland) 28, no. 9 (2023): 3690.

[23] H. Yuan, Q. Ma, L. Ye, et al., “The Traditional Medicine and Modern Medicine From Natural Products,” Molecules (Basel, Switzerland) 21, no. 5 (2016): 559.

[24] T. Hua, M. Yang, H. Song, et al., “Huc-MSCs-derived Exosomes Attenuate Inflammatory Pain by Regulating Microglia Pyroptosis and Autophagy via the miR-146a-5p/TRAF6 Axis,” Journal of Nanobiotechnology 20, no. 1 (2022): 324.

[25] C. Y. Taabazuing, M. C. Okondo, and D. A. Bachovchin, “Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages,” Cell Chemical Biology 24, no. 4 (2017): 507–514.

[26] K. He, T. Wan, D. Wang, et al., “Gasdermin D Licenses MHCII Induction to Maintain Food Tolerance in Small Intestine,” Cell 186, no. 14 (2023): 3033–3048.

[27] K. S. Putt, G. W. Chen, J. M. Pearson, et al., “Small-molecule Activation of Procaspase-3 to Caspase-3 as a Personalized Anticancer Strategy,” Nature Chemical Biology 2, no. 10 (2006): 543–550.

[28] Y. Zheng, J. Wang, Z. Ling, et al., “A Diagnostic Model for Sepsis-induced Acute Lung Injury Using a Consensus Machine Learning Approach and Its Therapeutic Implications,” Journal of Translational Medicine 21 (2023): 620.

[29] J. Y. Kang, M. M. Xu, Y. Sun, et al., “Melatonin Attenuates LPS-induced Pyroptosis in Acute Lung Injury by Inhibiting NLRP3-GSDMD Pathway via Activating Nrf2/HO-1 Signaling Axis,” International Immunopharmacology 109 (2022): 108782.

[30] S. Li, X. Xue, H. Zhang, et al., “Inhibition of Sphingosine Kinase 1 Attenuates LPS-induced Acute Lung Injury by Suppressing Endothelial Cell Pyroptosis,” Chemico-Biological Interactions 390 (2024): 110868.

[31] X. Hu, M. Zou, W. Zheng, et al., “Bhlhe40 deficiency Attenuates LPS-induced Acute Lung Injury Through Preventing Macrophage Pyroptosis,” Respiratory Research 25, no. 1 (2024): 100.

[32] E. K. Y. Fan and J. Fan, “Regulation of Alveolar Macrophage Death in Acute Lung Inflammation,” Respiratory Research 19 (2018): 50.

[33] T. Shay and J. Kang, “Immunological Genome Project and Systems Immunology,” Trends in Immunology 34, no. 12 (2013): 602–609.

[34] S. C. Cheng, J. Quintin, R. A. Cramer, et al., “mTOR- and HIF-1alpha-mediated Aerobic Glycolysis as Metabolic Basis for Trained Immunity,” Science 345, no. 6204 (2014): 1250684.

[35] E. Dann, N. C. Henderson, S. A. Teichmann, et al., “Differential Abundance Testing on Single-cell Data Using k-nearest Neighbor Graphs,” Nature Biotechnology 40, no. 2 (2022): 245–253.

[36] C. Wang and J. Ruan, “Mechanistic Insights Into Gasdermin Pore Formation and Regulation in Pyroptosis,” Journal of Molecular Biology 434, no. 4 (2022): 167297.

[37] Y. Tan, Q. Chen, X. Li, et al., “Pyroptosis: A New Paradigm of Cell Death for Fighting Against Cancer,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 153.

[38] S. Crunkhorn, “Gasdermin D Inhibitor Protects Against Sepsis,” Nature Reviews Drug Discovery 19, no. 6 (2020): 388.

[39] K. W. Chen, B. Demarco, R. Heilig, et al., “Extrinsic and Intrinsic Apoptosis Activate Pannexin-1 to Drive NLRP3 Inflammasome Assembly,” EMBO Journal 38, no. 10 (2019): e101638.

[40] S. J. Lee, J. S. You, A. Gharbi, et al., “IOX1 activity as Sepsis Therapy and an Antibiotic Against Multidrug-resistant Bacteria,” Scientific Reports 11, no. 1 (2021): 2942.

[41] B. Sun, M. Lei, J. Zhang, et al., “Acute Lung Injury Caused by Sepsis: How Does It Happen?,” Frontiers in Medicine (Lausanne) 10 (2023): 1289194.

[42] Y. Jiao, T. Zhang, C. Zhang, et al., “Exosomal miR-30d-5p of Neutrophils Induces M1 Macrophage Polarization and Primes Macrophage Pyroptosis in Sepsis-related Acute Lung Injury,” Critical Care 25, no. 1 (2021): 356.

[43] Q. Hu, S. Zhang, Y. Yang, et al., “Extracellular Vesicles in the Pathogenesis and Treatment of Acute Lung Injury,” Military Medical Research 9, no. 1 (2022): 61.

[44] M. Huang, S. Cai, and J. Su, “The Pathogenesis of Sepsis and Potential Therapeutic Targets,” International Journal of Molecular Sciences 20, no. 21 (2019): 5376.

[45] Y. Xu, J. Xin, Y. Sun, et al., “Mechanisms of Sepsis-Induced Acute Lung Injury and Advancements of Natural Small Molecules in Its Treatment,” Pharmaceuticals (Basel) 17, no. 4 (2024): 472.

[46] J. Lei, L. Wang, L. Zou, et al., “GDF3 Protects Mice Against Sepsis-Induced Acute Lung Injury by Suppression of Macrophage Pyroptosis,” Pharmaceuticals (Basel) 17 (2024): 268.

[47] X. Shi, T. Li, Y. Liu, et al., “HSF1 Protects Sepsis-Induced Acute Lung Injury by Inhibiting NLRP3 Inflammasome Activation,” Frontiers in Immunology 13 (2022): 781003.

[48] L. Hato, A. Vizcay, I. Eguren, et al., “Dendritic Cells in Cancer Immunology and Immunotherapy,” Cancers (Basel) 16, no. 5 (2024): 981.

[49] K. Shortman and Y. J. Liu, “Mouse and human Dendritic Cell Subtypes,” Nature Reviews Immunology 2, no. 3 (2002): 151–161.

[50] I. Zanoni, R. Ostuni, G. Capuano, et al., “CD14 regulates the Dendritic Cell Life Cycle After LPS Exposure Through NFAT Activation,” Nature 460, no. 7252 (2009): 264–268.

[51] C. Wei, W. Jiang, R. Wang, et al., “Brain Endothelial GSDMD Activation Mediates Inflammatory BBB Breakdown,” Nature 629 (2024): 8013.

[52] R. S. Gabarin, M. Li, P. A. Zimmel, et al., “Intracellular and Extracellular Lipopolysaccharide Signaling in Sepsis: Avenues for Novel Therapeutic Strategies,” Journal of Innate Immunity 13, no. 6 (2021): 323–332.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.